Get the Stockscreener App
0.4686
11.33%
0.0477
Pavmed Inc stock is traded at $0.4686, with a volume of 386.04K.
It is up +11.33% in the last 24 hours and down -20.31% over the past month.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
See More
Previous Close:
$0.4209
Open:
$0.42
24h Volume:
386.04K
Relative Volume:
2.13
Market Cap:
$8.01M
Revenue:
$4.03M
Net Income/Loss:
$24.32M
P/E Ratio:
-0.109
EPS:
-4.3008
Net Cash Flow:
$-45.76M
1W Performance:
+4.18%
1M Performance:
-20.31%
6M Performance:
-40.82%
1Y Performance:
-31.51%
1-Day Range:
$0.42
$0.475
1-Week Range:
$0.41
$0.475
52-Week Range:
$0.304
$1.90
Pavmed Inc Stock (PAVM) Company Profile
Name
Pavmed Inc
Sector
Industry
Phone
(212) 949-4319
Address
360 MADISON AVENUE, NEW YORK, NY
Compare PAVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
0.4686 | 7.46M | 4.03M | 24.32M | -45.76M | -4.3008 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-05-20 | Initiated | Ascendiant Capital Markets | Buy |
| Jun-28-18 | Initiated | Maxim Group | Buy |
Pavmed Inc Stock (PAVM) Latest News
Lucid Diagnostics Reports Q2 2025 Financial Results - MSN
What institutional flow reveals about PAVmed Inc.2025 Stock Rankings & Daily Entry Point Trade Alerts - Newser
Multi factor analysis applied to PAVmed Inc.Chart Signals & AI Enhanced Market Trend Forecasts - Newser
Best data tools to analyze PAVmed Inc. stock2025 Biggest Moves & Real-Time Volume Triggers - Newser
How to build a dashboard for PAVmed Inc. stockJuly 2025 Trade Ideas & Capital Efficient Trading Techniques - Newser
What technical models suggest about PAVmed Inc.’s comebackWeekly Trend Report & Technical Entry and Exit Tips - Newser
Heatmap Data Shows High Activity in PAVmed Inc. SectorMarket Performance Summary & Free Growth Oriented Trading Recommendations - thegnnews.com
PAVmed Reports Q2 2025 Financial Results and Developments - MSN
Visual trend scoring systems applied to PAVmed Inc.2025 Trade Ideas & Daily Profit Focused Stock Screening - Newser
Trendline Breach Raises Concern for PAVmed Inc. InvestorsJuly 2025 Rallies & Fast Gain Stock Trading Tips - 선데이타임즈
Maxim Group Reiterates Buy Rating on PAVmed with $9.75 Average Price Target - AInvest
Forecasting PAVmed Inc. price range with options dataStock Surge & Free Technical Confirmation Trade Alerts - Newser
Is it too late to sell PAVmed Inc.2025 EndofYear Setup & Stock Portfolio Risk Control - Newser
PAVmed Q2 Earnings Miss Expectations; Market Reaction Remains Cautious - AInvest
Published on: 2025-08-17 02:05:32 - Newser
What moving averages say about PAVmed Inc.July 2025 Action & Weekly Top Stock Performers List - Newser
Full technical analysis of PAVmed Inc. stockMarket Performance Recap & Risk Controlled Swing Trade Alerts - Newser
Is PAVmed Inc. the Top Chart Pick This WeekWeekly Stock Report & AI Forecasted Entry and Exit Points - metal.it
Why PAVmed Inc. stock attracts strong analyst attentionMarket Performance Summary & Consistent Growth Stock Picks - Newser
Technical analysis overview for PAVmed Inc. stockGap Down & Safe Entry Point Alerts - Newser
PAVmed reports Q2 non-GAAP EPS (5c) vs. (84c) last year - MSN
Published on: 2025-08-15 16:28:42 - Newser
PAVmed Reports Q2 2025 Financial Results: $13.3M Net Loss, $1.2M in Lucid Diagnostics Revenue - AInvest
Lucid Diagnostics shares rise 2.04% intraday after securing capital to extend runway past key reimbursement milestones. - AInvest
PAVmed Q2 2025 slides reveal dramatic cost reduction amid Lucid Diagnostics growth - Investing.com Nigeria
PAVmed Q2 2025 slides reveal dramatic cost reduction amid Lucid Diagnostics growth By Investing.com - Investing.com South Africa
PAVmed Inc (PAVM) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... By GuruFocus - Investing.com Canada
PAVmed 2025 Q2 Earnings Net Loss Narrows by 17.4% - AInvest
Lucid Diagnostics Advances Towards Medicare Coverage - MSN
PAVmed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
PAVmed Revenue Jumps 513% in Q2 - sharewise.com
PAVmed Reports Q2 2025 Financial Results, Lucid Diagnostics Recognizes $1.2M in Revenue and Processes 2,756 Tests - AInvest
Press Release: PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results - 富途牛牛
PAVmed Inc. SEC 10-Q Report - TradingView
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results - BioSpace
PAVmed's Q2 2025 Earnings Call: Unraveling Contradictions in Medicare Strategy, FDA Timelines, and Biopharma Expansion - AInvest
Transcript : PAVmed Inc., Lucid Diagnostics Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
Earnings call transcript: Lucid Diagnostics highlights Q2 2025 growth and Medicare focus - Investing.com India
Lucid Diagnostics Inc: Navigating Earnings Challenges and Strategic Growth in a Competitive Diagnostics Landscape - AInvest
What makes PAVmed Inc. stock price move sharplyShort-Term Explosive Growth - thegnnews.com
PAVmed's Q2 2025 Earnings: A Strategic Inflection Point in Healthcare Innovation and Financial Turnaround - AInvest
PAVmed PAVM 2025Q2 Earnings Preview Upside Potential Driven by Strategic Innovations - AInvest
Investors Hope for Bounce in PAVmed Inc. After SelloffCapital Preservation Forecast Insight Signal - beatles.ru
PAVmed (PAVM) to Release Quarterly Earnings on Thursday - Defense World
Lucid Diagnostics to Participate in Upcoming Investor Conferences - Eastern Progress
Published on: 2025-08-05 15:46:56 - metal.it
Lucid Diagnostics to Participate in Upcoming Investor Conferences – Company Announcement - Financial Times
Lucid Diagnostics To Participate In Upcoming Investor Conferences - Barchart.com
Head-To-Head Review: TearLab (OTCMKTS:TEAR) and PAVmed (NASDAQ:PAVM) - Defense World
PAVmed Inc. Forms Bullish Flag — Upside AheadEntry Plan for Oversold Reversal Stocks Released - metal.it
PAVmed Inc. Crosses 200 Day MA — Signal or NoiseReal-Time Analysis With Entry Targets In Progress - metal.it
Pavmed Inc Stock (PAVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):